According to a report by IWSR, the leader in global beverage alcohol data and insights, no- and low-alcohol consumption across the world's leading 10 no/low markets, which account for approximately 70% of global no/low-alcohol volumes, grew by +5% in volume in 2023, and the market is now worth over $13 billion. The .no/low alcohol category is forecast to grow at a volume CAGR of +6% between 2023 and 2027 Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock ".E ...

Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health issues, including alcohol use disorder [5][6] - The company has a robust intellectual property portfolio consisting of eighteen patent families and 27 granted patents, with plans to seek additional patents as needed [2] Product Development - Clearmind's proprietary MEAI-based alcohol substitute beverage program has advanced, with patents granted in the U.S., India, and Europe [2] - The company is in the final stages of a pre-clinical study required for a novel-food application submission, complying with global regulations for novel foods and food additives [4] Market Insights - The no- and low-alcohol consumption market, which accounts for approximately 70% of global volumes, grew by 5% in volume in 2023, reaching a market value of over $13 billion [5] - The no/low alcohol category is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2027 [5]

The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed most of the pr ...

Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further ...

Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) ("Clearmind" or the "Company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it will apply to the British Columbia Securities Commission (the "BCSC"), as principal regulator, the Ontario Securities Commission (the "OSC"), as non-principal regulator, and the Alberta ...

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step in harnessing generation 3.0 psychedelic c ...

Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of  3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon) ("3 ...

Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today provided the following letter to shareholders from the Company's CEO, Dr. Adi Zuloff-Shani: "In 2023, Clearmind made significant advances on its groundbreaking journey, propelling our flagship compound, CMND-100 ...

Exhibit 99.1 (Unaudited) CLEARMIND MEDICINE INC. | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------|--------------|---------------| | Assets | | 2024 | 2023 | | Current assets | | | | | Cash and cash equivalents | $ | 9,285,973 | $ 5,427,739 | | Other receivables | | 68,491 | 104,320 | | Short-term investment (Note 3) | | 86,668 | 86,112 | | Prepaid expenses | | 316,886 | 40,403 | | Related parties (N ...

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methox ...